127 related articles for article (PubMed ID: 4087034)
1. Immunomodulatory effects of poly(I,C)-LC in cancer patients.
Maluish AE; Reid JW; Crisp EA; Overton WR; Levy H; Foon KA; Herberman RB
J Biol Response Mod; 1985 Dec; 4(6):656-63. PubMed ID: 4087034
[TBL] [Abstract][Full Text] [Related]
2. Phase I trials of poly(I,C) complexes in advanced cancer.
Krown SE; Kerr D; Stewart WE; Field AK; Oettgen HF
J Biol Response Mod; 1985 Dec; 4(6):640-9. PubMed ID: 2418162
[TBL] [Abstract][Full Text] [Related]
3. A phase I evaluation of poly(I,C)-LC in cancer patients.
Stevenson HC; Abrams PG; Schoenberger CS; Smalley RB; Herberman RB; Foon KA
J Biol Response Mod; 1985 Dec; 4(6):650-5. PubMed ID: 2418163
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].
Chirigos MA; Schlick E; Ruffmann R; Budzynski W; Sinibaldi P; Gruys E
J Biol Response Mod; 1985 Dec; 4(6):621-7. PubMed ID: 4087033
[TBL] [Abstract][Full Text] [Related]
5. Optimization of an immunotherapeutic protocol with poly(I,C)-LC.
Talmadge JE; Hartmann D
J Biol Response Mod; 1985 Oct; 4(5):484-9. PubMed ID: 4078594
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.
Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Chirigos M
Cancer Res; 1985 Mar; 45(3):1066-72. PubMed ID: 3971361
[TBL] [Abstract][Full Text] [Related]
7. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.
Hawkins MJ; Levin M; Borden EC
J Biol Response Mod; 1985 Dec; 4(6):664-8. PubMed ID: 2418164
[TBL] [Abstract][Full Text] [Related]
8. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.
Ewel CH; Urba WJ; Kopp WC; Smith JW; Steis RG; Rossio JL; Longo DL; Jones MJ; Alvord WG; Pinsky CM
Cancer Res; 1992 Jun; 52(11):3005-10. PubMed ID: 1591717
[TBL] [Abstract][Full Text] [Related]
9. Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I,C)-LC].
Black PL; Hartmann D; Pennington R; Phillips H; Schneider M; Tribble HR; Talmadge JE
Int J Immunopharmacol; 1992 Nov; 14(8):1341-53. PubMed ID: 1464467
[TBL] [Abstract][Full Text] [Related]
10. The effect of interferon on rabies infection of animals.
Baer GM
Tex Rep Biol Med; 1981-1982; 41():526-31. PubMed ID: 6189218
[No Abstract] [Full Text] [Related]
11. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma.
Durie BG; Levy HB; Voakes J; Jett JR; Levine AS
J Biol Response Mod; 1985 Oct; 4(5):518-24. PubMed ID: 3935757
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.
Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Schlick E; Ruffmann R; Wiltrout RH; Chirigos MA
Cancer Res; 1985 Mar; 45(3):1058-65. PubMed ID: 3155990
[TBL] [Abstract][Full Text] [Related]
13. Activation of natural killer cells in newborn piglets by interferon induction.
Lesnick CE; Derbyshire JB
Vet Immunol Immunopathol; 1988 Mar; 18(2):109-17. PubMed ID: 2838948
[TBL] [Abstract][Full Text] [Related]
14. Interferons and interferon inducers in cancer treatment.
Krown SE
Semin Oncol; 1986 Jun; 13(2):207-17. PubMed ID: 2424089
[No Abstract] [Full Text] [Related]
15. [Antitumor effect of Corynebacterium parvum and poly ICLC on experimental brain tumors].
Kiya K; Kitaoka T; Okamoto H; Harada K; Uozumi T; Toge T; Hattori T; Machida H
Neurol Med Chir (Tokyo); 1983 Nov; 23(11):841-8. PubMed ID: 6201759
[No Abstract] [Full Text] [Related]
16. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer.
Theriault RL; Hortobagyi GN; Buzdar AU; Levy HB; Hersh EM
Cancer Treat Rep; 1986 Nov; 70(11):1341-2. PubMed ID: 3768878
[No Abstract] [Full Text] [Related]
17. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
Kende M
J Biol Response Mod; 1985 Oct; 4(5):503-11. PubMed ID: 2416883
[TBL] [Abstract][Full Text] [Related]
18. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
[TBL] [Abstract][Full Text] [Related]
20. Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes.
Crane LR; Levy HB; Lerner AM
Antimicrob Agents Chemother; 1982 Mar; 21(3):481-5. PubMed ID: 7049075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
